Expressions of epidermal growth factor receptor, matrix metalloproteinase-2 and matrix metalloproteinase-9 in bladder carcinoma

Journal of Biological Sciences

Volumn 6, Issue 5, 2006, Pages 911-915

  El Kenawy, Ayman El Meghawry ^a,d   El Kott, Attalla Farag ^b   Bin Meferij, Mashael Mohammed ^c   El Gamal, Ezz Mohie ^d  

^a MENOUFIA UNIVERSITY   (Egypt)

^b Fayoum University   (Egypt)

^c Girls College of Education Riyadh   (Saudi Arabia)

^d MANSOURA UNIVERSITY   (Egypt)

Author keywords

Bladder cancer; EGFr; MMP 2; MMP 9; Prognosis

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; MONOCLONAL ANTIBODY; PARAFFIN;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE SECTION;

EID: 33847008622     PISSN: 17273048     EISSN: 18125719     Source Type: Journal    
DOI: 10.3923/jbs.2006.911.915     Document Type: Article

References (12)

1. Colquhoun, A.J. and J.K. Mellon, 2002. Epidermal growth factor receptor and bladder cancer. Postgrad Med. J., 78: 584-589.
2. Cotran, R.S., V. Kumar and S.I. Robbins, 1994. The Lower Urinary Tract. In: Robbins Pathologic Basis of Diseases. 5th, Edn., Saunders, W.B., Co. Lonon. Philadelphia, Toronto. Tokyo. Chapter 21, pp: 991.
3. Gerhards, S., K. Jung and F. Koening et al., 2001. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with high stage and grade of bladder carcinoma. Urology, 57: 675-679.
4. Grignon, D.J., W. Sakr and M. Toth et al., 1996. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res., 56: 1654-1659.
5. Hsu, S.M., L. Raine and H. Fanger, 1981. The use of avidinbiotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem Cytochem., 29: 557-588.
6. Inoue, K., M. Kamada and J.W. Salton et al., 2002. The prognostic alue of angiogenesis and metastasis-related genes for progression f transitional cell carcinoma of the renal pelvis and ureter. Lin Cancer Res., 8: 1863-1870.
7. Kanayama, H., K. Yokota and Y. Kurokawa et al., 1998. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer, 82: 1359-1366.
8. Kaplan, E.L. and P. Meier, 1958. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481.
9. Nakanishi, K., T. Kawai and H. Sato et al., 2000. Expression of matrix metalloproteinase-2 (MMP-2) and of membrane-type-1 matrix metalloproteinase (MT1-MMP) in transitional cell carcinoma of the upper urinary tract. Hum. Pathol., 31: 193-200.
10. Nicholson, R.I., J.M.W. Gee and M.E. Harper, 2001. EGFR and cancer prognosis. Eur. J. Can., 37: S9-S15.
11. Penault-Llorca, F., X. Durando and J.O. Bay, 2003. Prognostic value of epidermal growth factor receptor. Bull. Cancer, 90: S192-196.
12. Yasuyoshi, M., K. Shigeru and N. Koichiro et al., 2004. Expression of metalloproteinase-2, metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: Correlation with tumor stage and survival. Urology, 63: 602-608.